Sign In
Buy APLM
$22.83
+5.33 (+30.47%)
At Close: Jun 22, 2026
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
08:00am, Monday, 27'th Apr 2026
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than
Apollomics Inc. Announces $2.0 Million Bridge Financing
07:00am, Wednesday, 01'st Apr 2026
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Conver
Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March
02:50am, Saturday, 28'th Mar 2026
Apollomics Inc. (NASDAQ: APLM - Get Free Report) was the target of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,621 shares, a decline
Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest
03:17am, Wednesday, 18'th Mar 2026
Apollomics Inc. (NASDAQ: APLM - Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 12,471 shares,
Apollomics Reports First Half 2025 Financial Results
04:05pm, Monday, 22'nd Dec 2025
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple onco
Apollomics Announces Settlement of Cayman Litigation
05:38pm, Wednesday, 19'th Nov 2025
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Ag
Apollomics Announces Changes to its Board of Directors and Composition of Committees
11:00pm, Monday, 17'th Nov 2025
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today a
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
02:36pm, Wednesday, 15'th Oct 2025
FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developi
Nasdaq Resumes Trading in Apollomics Inc.
04:05pm, Tuesday, 14'th Oct 2025
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq:
Apollomics, Inc. Company Operational Continuity Update
09:22pm, Monday, 13'th Oct 2025
FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update.
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
04:05pm, Thursday, 03'rd Apr 2025
FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
08:00am, Monday, 31'st Mar 2025
FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncolo
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncol
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
04:05pm, Tuesday, 10'th Dec 2024
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04:05pm, Wednesday, 04'th Sep 2024
FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple onco
